We’re deep into October and still no news of what’s happening with Sputnik V yet from Stelis. Hadn’t they said that the first dose will be out by October?
Q2 results are anyway likely to be soft as per the guidance in the last quarter (not sure if the Endo portfolio is already integrated). Plus there are some disruptions and costs may be high.